Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.
Micke P, et al. Among authors: ponten f.
Int J Cancer. 2014 Nov 1;135(9):2206-14. doi: 10.1002/ijc.28857. Epub 2014 Apr 8.
Int J Cancer. 2014.
PMID: 24710653
Free article.